key: cord-0705406-1yuu0v6e
authors: Mohta, Alpana; Sharma, Manoj Kumar; Ghiya, Bhikam Chand; Mehta, Rajesh Dutt
title: Clinical, histopathological, and dermatoscopic characterization of eruptive pseudoangioma developing after COVID‐19 vaccination—A case‐series
date: 2022-02-28
journal: J Cosmet Dermatol
DOI: 10.1111/jocd.14870
sha: 500afdce4624eed93c660bd9d28d6140356688ec
doc_id: 705406
cord_uid: 1yuu0v6e

nan

To the Editor, Eruptive pseudoangioma (EP) is an acute, benign, self-limiting exanthem characterized by the sudden appearance of small cherry angioma-like lesions over the body. EP develops due to transient dilatation of dermal blood vessels as a result of "dermal hypersensitivity reaction". Reported for the first time by Cherry et al. 1 EP is believed to be a paraviral dermatosis. The role of insect bite hypersensitivity reaction has also been suggested. Often pediatric patients may experience prodromal symptoms, but adult cases are invariable asymptomatic. Cases of EP following COVID-19 have been sparsely reported. 2,3 Till date, only 6 cases of EP secondary to COVID-19 vaccine have been reported in literature. 4, 5 The proposed hypothesis is upregulation of cellular and humoral immunity against the spike protein in the viral vaccine stimulating a paraviral response. 5 In our experience, the estimated incidence of EP following COVID-19 vaccination is as low as 0.03%.

According to our results, EP is predominantly a disease of younger age groups. Corticosteroid-induced immunosuppression has also been postulated to trigger EP. 1 However, none of our patients had history of acquired or iatrogenic immunosuppression. The interesting observation of concurrent dengue fever in 3 patients reinforces the multidimensional paraviral pathomechanics.

In conclusion, our work simply aims at elucidating a new facet of the possible immunization-related pathogenesis at play in causing EP. The benefits of these vaccines exceedingly outweigh these adverse events. However, since lesions of EP can mimic vasculitis, adrenergic urticaria, and vaccine-induced thrombotic thrombocytopenia, all cases must be subjected to histopathological confirmation.

Lack of controls and inability to assign causality were a few limitations of our work.

COVID-19, COVID-19 vaccine, eruptive pseudoangioma, eruptive pseudoangiomatosis, SARS-CoV-2

Due ethical approval was taken from institutional ethics committee. All patients gave written informed consent to be a part of this study.

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

Eruptive pseudoangiomatosis -Cherry angiomas with perilesional halo

Eruptive pseudoangiomatosis and SARS-CoV-2 (COVID-19) infection

An observational study of mucocutaneous manifestations among SARS-CoV-2 patients from three COVID-19 dedicated tertiary care centers

Comment on 'development of eruptive pseudoangiomatosis following COVID-19 inmunizationapropos of 5 cases': could eruptive pseudoangiomatosis represent a paraviral eruption associated with SARS-CoV-2?

Development of eruptive pseudoangiomatosis following COVID-19 immunization -Apropos of 5 cases